Background {#Sec1}
==========

Breast cancer is the most frequently diagnosed cancer among women, which contributed to 25 % of all cancer cases in women worldwide, and it is the leading cause of female cancer-related death \[[@CR1]\]. In UK, 48,034 women were diagnosed as breast cancer holders in 2008, and in USA, more than 2.8 million women suffered from breast cancer in 2015 \[[@CR2], [@CR3]\]. In China, breast cancer mortality have also raised quickly in recent years, from 3.53/100,000 in 1990--1992 to 4.25 in 2012 \[[@CR4]\]. The high morbidity and mortality of the disease lead to increasing global public health burden gradually. It is widely accepted that several factors, such as hormonal, environmental, and genetic factors as well as their interactions contribute to the onset of breast cancer \[[@CR5], [@CR6]\]. In 1993, mutations in breast cancer (*BRCA1)* gene were suggested to be linked with high incidence of breast cancer in some families \[[@CR7]\]. Since then, many susceptible genes involved in initiation and evolution of breast cancer have been researched, and one of them, the *methylenetetrahydrofolate reductase* (*MTHFR*) gene has been widely studied.

The *MTHFR* locus locates on chromosome 1 at the end of short arm (1p36.6), which encodes enzymes relevant to folates metabolism. The enzyme encoded by *MTHFR* gene takes part in the irreversible conversion of 5,10-metylenetetrahydrofolate to 5-methyltetrahydrofolate, which plays a crucial role in homocysteine remethylation to methionine \[[@CR8]\]. Previous studies have indicated that functional single nucleotide polymorphisms (SNPs) of *MTHFR* gene participate in the folate-metabolizing genetic pathway and are fundamental during the synthesis, repair, and methylation process of DNA, RNA, and protein, which may affect folate and vitamin B~12~ level \[[@CR9], [@CR10]\]. Of these SNPs, *1298A\>C* polymorphism is caused by A to C transition in exon 7 and results in alanine in substitution of glutamine at codon 429 of the protein \[[@CR11]\]. Subjects with mutated *MTHFR 1298A\>C* genetic polymorphisms have higher plasma level of homocysteine \[[@CR12]\] and may be more susceptible to different kinds of cancers, including breast cancer.

Many studies have investigated the association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer risk. However, the results are inconsistent, with some studies found significant association \[[@CR13], [@CR14]\], while others were not \[[@CR15], [@CR16]\]. Although previous meta-analysis has tried to clarify the association \[[@CR17]\], recently, several new case-control studies have been published \[[@CR18]--[@CR20]\]. In order to avoid the limitations of single case-control studies and provide renewed evidence, we performed this updated meta-analysis and tried to give a more precise and comprehensive estimation of association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

Two databases were electronically searched, including PubMed and EMBASE, to retrieve studies analyzing the association between breast cancer susceptibility and *MTHFR* gene *1298A\>C* polymorphism until January 1, 2016. Searching terms were "breast cancer" or "breast neoplasm", in combination with "*methylenetetrahydrofolate reductase*" or "*MTHFR*" or "*MTHFR A1298C*" or "*MTHFR 1298A\>C*" or "*rs1801131*" or "*Glu429Ala*", and in combination with, "polymorphism" or "variant" or "genotype" or "allele". We also hand-checked the reference lists of all the included studies to make sure no study was missed. Two researches conducted the searches independently. If several publications carried out among same patients and controls, we only included one study with the most complete data.

Inclusion criteria {#Sec4}
------------------

We first performed initial screening of titles and abstract. A second round screening was based on full-text reviews. Studies were considered eligible if they met the following criteria: (1) it was a case-control study in design; (2) it evaluated the *MTHFR* gene *1298 A\>*C polymorphism and breast cancer susceptibility; (3) breast cancer was pathologically confirmed for all of the patients; (4) sample sizes and individual genotype frequencies in cases and controls were available; and (5) cases and controls should be matched.

Exclusion criteria {#Sec5}
------------------

Researches were excluded if they met any one of the following criteria: (1) data came from reviews or abstracts; (2) genotype and allele frequencies were both unavailable; (3) subjects with other malignant tumor were included in controls; (4) repeatedly published literature; (5) not breast cancer susceptibility outcome; and (6) controls were chosen from women with a family history of breast cancer or with other kinds of malignant tumors.

Data extraction and quality assessment {#Sec6}
--------------------------------------

Two reviewers independently searched and selected literature, and then, extracted relevant data according to a data extraction form. Disagreements were solved by discussion until consensus was made. The extracted data including the first author, year of publication, country of origin, ethnicity of the study population, source of control, sample size, the genotype and allele frequencies of the *MTHFR* gene *1298A\>C* polymorphism, and information of Hardy-Weinberg equilibrium (HWE) in control groups. Different ethnicity descents were categorized as Caucasian, Asian, African, and if studies were with more than one ethnicity, they were categorized as mixed ethnicity.

For each included study, the quality assessment was conducted according to the STrengthening the REporting of Genetic Association (STREGA) studies). If the study met all or most of the criteria in this approach, it would be classified as "++" or "high quality". For study in which some of the criteria were fulfilled and the others were not likely to change the results and conclusions, it would be graded as "+" or "moderate quality". For studies fulfilled few or no criteria and the results were thought to be with non-ignorable bias, it would be classified as "−" or "low quality" \[[@CR21]\].

Statistical analysis {#Sec7}
--------------------

Data analysis was conducted using STATA 11.0 software (Stata Statistical software, College Station, TX, USA, [www.stata.com](http://www.stata.com/)). Odds ratio (OR) and its corresponding 95 % confidence intervals (95 % CI) were used to evaluate the strength of association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility. Heterogeneity among included studies was tested using chi-square-based *Q* test and *I*^2^ test. *P*~het~ \< 0.05 or *I*^2^ \> 50 % were considered as statistically significant for heterogeneity. The Mantel-Haenszel method was used for fix-effect model if no heterogeneity was found. Otherwise, the DerSimonian-Laird random-effect model was used. Fix-effect model considers that across all studies, the genetic factors have similar effects on genetic disorder susceptibility and the observed differences among studies are caused just by chance \[[@CR22]\]. Random-effect model considers that different studies may have substantial diversity, and it calculates within- as well as between-study difference \[[@CR23]\]. Five comparison genetic models were used to assess the association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility. We assessed the dominant model (AA + AC vs. CC), recessive model (AA vs. AC + CC), allele contrast genetic model (A vs. C), the heterozygote comparison (AC vs. CC), and the homozygote comparison (AA vs. CC). *P* \< 0.05 showed the statistical significance. HWE was tested for included studies if no relevant information was provided in original research. Sensitivity analyses were conducted by omitting individual studies sequentially. Moreover, we performed subgroup analysis stratified by ethnicity, source of control, and deviation from HWE. Publication bias was quantitatively assessed by Egger's linear regression test \[[@CR24]\] and visual inspection of Begg's funnel plots.

Results {#Sec8}
=======

Literature search {#Sec9}
-----------------

We initially identified 373 potentially relevant studies from searching the two databases and the reference lists of relevant studies. Firstly, we eliminated duplications, and after this procedure, 248 studies were retained. After reading the titles and abstracts, we excluded 193 studies. Among them, 89 were not case-control studies, 91 were irrelevant to *MTHFR* polymorphism or breast cancer susceptibility, and 13 were reviews or meta-analysis. Then, we read the full texts of the 55 retained articles and 17 were excluded. Of them, 11 was irrelevant to *1298A\>C* polymorphism, four focused on breast cancer mortality, one conducted among the same patients and controls with another study, but provided less completed data, and for one study, the controls were chosen from *BRCA1* carriers. We finally identified 38 case-control studies eligible for the meta-analysis \[[@CR13]--[@CR16], [@CR18]--[@CR20], [@CR25]--[@CR55]\], including 18,686 cases and 22,299 controls. A flow chart of data selection was presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart of data selection

Main characteristics of included studies {#Sec10}
----------------------------------------

Table [1](#Tab1){ref-type="table"} presents the main characteristics and genotype frequencies of the included studies. Of the 38 studies, 15 studies were carried out among Asians, 13 among Caucasians, and 10 among mixed populations. All studies included were case-control studies in design, and all patients with breast cancer fulfilled the pathological diagnosis. The number ranged from 35 to 1986 for cases, and 33 to 2414 for controls. In 21 studies, controls were normal healthy people randomly recruited from general population, and in 15 studies, controls were recruited from hospital among women with benign disease or through women going to hospital for routine physical examines, but in the two studies, we were unable to find out the source of controls. In most of the included studies, controls were matched with cases in ethnicity and age. In quality assessment, 17 studies included were categorized as "high quality," and 21 as "moderate quality" (Table [1](#Tab1){ref-type="table"}). In eight studies, the genotype distributions in control groups were deviated from HWE (Table [1](#Tab1){ref-type="table"}).Table 1The main characteristics of studies included in this meta-analysis and the distribution of *MTHFR* gene *1298A\>*C genotypes and alleles among cases and controlsFirst authorYearEthnicitySource of controlsCasesControlsCasesControlsDeviation from HWEQuality gradeAAACCCAAACCCACACAram2012CaucasianHB355520307551259513585Yes+Awwad2015AsianPB6861175864131979518090No++Carvalho Barbosa Rde2012MixedPB68801772849216114228102Yes+Chen2005MixedPB5584178753645711015335911529677No++Cheng2008AsianHB2071251931020717539163827241Yes+Chou2006AsianHB104308172951823846439131No+Ergul2003CaucasianHB50482090851814888265121No+Ericson2009CaucasianPB242242574874801057263561454690No++Forsti2004CaucasianNA941022713312738290156393203No+Gao2009AsianPB44616594251881110571831038210No++He2014AsianHB1381324017315553408212501261No+Hosseini2011CaucasianHB369616260135105168420255345No+Inoue2008AsianPB22513916387234415891711008316No++Justenhoven2005CaucasianPB2732565329526673802362856412No++Kakkoura2015MixedPB13846546815050048474114018001468No++Kotsopoulos2008CaucasianHB466390853983097313225601105455No+Lajin2012CaucasianHB4452236548131409817874No+Le Marchand2004MixedPB741372771493801120185452637871041No++Lissowska2007CaucasianPB89287422010869412512658131431131443Yes+Liu2013AsianHB2061765321417249588282600270No+Lopez-Cortes2015MixPB110311913122353855Yes+Lu2015AsianHB3691721935218523910210889231No+Ma2009MixedHB2691682127915722706210715201No+Mir2008AsianNA151911122049214422Yes+Ozen2013MixPB1729571350633917735Yes+Papandreou2012CaucasianHB1291353613611631393207388178No+Platek2009MixPB44340283842758181128856824421120No++Qi2004AsianPB1555841447133686635977No++Sangrajrang2010AsianHB3022233825820623827299722252Yes+Sharp2002CaucasianPB2725324251179317347No++Shrubsole2004AsianPB768311428243444018473951992424No++Stevens2007MixedPB2242284225220140676312705281No++Vainer2010CaucasianHB398353803793307611495131088482No+Weiwei2014AsianHB1351293215113025399193432180No+Wu2012AsianPB37326422851064411238No++Xu2007MixedPB5584178753645711015335911529677No++Zhang2015AsianPB9887311058427283149294138No++Ziva Cerne2011CaucasianPB2582194713111721735313379159No++*PB* population-based study, *HB* hospital-based study, *NA* not available, *HWE* Hardy-Weinberg equilibrium

Quantitative data analysis {#Sec11}
--------------------------

### Association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility {#Sec12}

The results of the five genetic models testing *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility are presented in Table [2](#Tab2){ref-type="table"}. In the dominant model (AA + AC vs. CC), *P* value for heterogeneity was 0.000, and *I*^2^ was 50.5 %, indicating significant heterogeneity among studies. Thus, random-effect model was used. The overall effect *Z* value was 1.12 (*P* = 0.218) and OR was 0.99 (95 % CI 0.99--1.00), suggesting that no association was found in the dominant model. The Egger's linear regression test indicated that there was some evidence of publication bias in this model (Egger, *P* = 0.01). Other four genetic models were also performed (Table [2](#Tab2){ref-type="table"}), but no association was found. In subgroup analyses stratified by source of control, a significant decrease in breast cancer susceptibility was found in hospital-based controls in dominant model (OR = 0.98, 95 % CI 0.96--1.00, *P* = 0.037), but not in allele contrast genetic model (OR = 0.97, 95 % CI 0.94--1.00, *P* = 0.092) (Table [3](#Tab3){ref-type="table"}). Moreover, the results showed that in subgroups of Asians and population-based studies, the heterogeneity among studies was significantly reduced. Figure [2](#Fig2){ref-type="fig"} shows the forest plot of the dominant model testing the association between *MTHFR 1298A\>C* polymorphism and breast cancer risk, stratified by ethnicity. Figure [3](#Fig3){ref-type="fig"} shows the forest plot of the dominant model testing the association between *MTHFR 1298A\>C* polymorphism and breast cancer risk, stratified by source of control.Table 2Summary of different genetic model comparison results of *MTHFR* gene *1298A\>C* polymorphismGenetic modelOR (95 % CI)*ZP* value*I* ^2^ %*P* ~het~Effect modelEgger's test*t* value*P* valueAA + AC vs. CC0.99 (0.99--1.00)1.230.21850.50.000R−2.720.010AA vs. AC + CC1.00 (0.97--1.02)0.150.88035.90.016R−1.450.155AA vs. CC0.99 (0.98--1.01)0.860.39043.80.002R−2.750.014AC vs. CC0.99 (0.97--1.00)1.480.13841.20.005R−2.550.015A vs. C0.99 (0.98--1.01)0.920.36055.50.000R−2.270.029*OR* odds ratio, *CI* confidence interval, *R* random-effect model, *P* ~het~ *P* value for heterogeneity*P* \< 0.05 stands for statistical significanceTable 3Results of subgroup analyses of *MTHFR* gene *1298A\>C* polymorphismStratified byComparisonNumber of datasetsDominant genetic modelAllele contrastOR (95 % CI)*P* valueOR (95 % CI)*P* valueEthnicityAsian151.00 (0.99--1.00)0.5061.01 (0.99--1.02)0.249Caucasian130.98 (0.95--1.01)0.1290.97 (0.93--1.00)0.059Mixed100.99 (0.99--1.00)0.8520.99 (0.98--1.01)0.660Source of controlPB211.00 (0.99--1.01)0.9311.00 (0.99--1.02)0.830HB150.98 (0.96--1.00)0.0370.97 (0.94--1.00)0.092NA20.99 (0.94--1.04)0.7930.99 (0.91--1.08)0.892Deviation from HWEYes80.98 (0.95--1.00)0.0190.98 (0.95--1.01)0.102No301.00 (0.99--1.01)0.9091.00 (0.98--1.01)0.801*PB* population-based study, *HB* hospital-based study, *NA* not availableFig. 2Shows the forest plot of the dominant model testing the association between *MTHFR 1298A\>C* polymorphism and breast cancer risk, stratified by ethnicityFig. 3Shows the forest plot of the dominant model testing the association between *MTHFR 1298A\>C* polymorphism and breast cancer risk, stratified by source of control

### Sensitivity analysis and publication bias {#Sec13}

Sensitivity analyses were conducted by omitting each dataset sequentially, and the result did not change under any genetic model. Sensitivity analysis suggested that for all of the five genetic comparisons of *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility, the results were statistically robust.

Visual inspection of Begg's funnel plots identified the substantial asymmetry for dominant model, the allele contrast genetic model, the heterozygote comparison, and the homozygote comparison. The Egger's linear regression test also indicated the similar results (*P* \< 0.05 for all models tested except the recessive genetic model) (Table [2](#Tab2){ref-type="table"}). Figure [4](#Fig4){ref-type="fig"} shows the Begg's funnel plot under dominant model of *MTHFR 1298A\>C* polymorphism.Fig. 4Begg's funnel plot under dominant model of *MTHFR 1298A\>C* polymorphism

Discussion {#Sec14}
==========

*MTHFR* is an essential gene in the one-carbon metabolism pathway. During the past few years, many meta-analyses assessing the association between *MTHFR* gene polymorphism and cancer risks have been published, including liver cancer, ovary cancer, lung cancer, gastric cancer, pancreatic cancer, cervical cancer, and esophageal cancer \[[@CR56]--[@CR60]\]. Genetic variation in enzymes and proteins involved in folate metabolism is also a rational candidate for studying the genetic of breast cancer. Therefore, the interest in *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility has existed for a long time. In 2002, Sharp et al. for the first time published a case-control study estimating the association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer risk. Their result suggested that risk was significantly lower for the *1298CC* genotype compared to *AA* genotype (OR = 0.24, 95 % CI 0.06--0.97) \[[@CR49]\]. However, after that, a number of subsequent studies were conducted and their results were inconsistent, with some studies showed significant associations while others were not. The inconsistency may be caused by several reasons. First of all, although in vitro, the variant genotype is associated with a substantial decrease in enzymatic activity \[[@CR11]\], this functional polymorphism may be an important but not the exclusive influencing factor in etiology and pathogenesis of breast cancer. Special lifestyle and environmental factors, such as tea drinking \[[@CR61]\], dietary intake of folate, vitamin B~6~ and B~12~ \[[@CR62]\], physical activities \[[@CR63]\], long-term oral contraceptive use \[[@CR64]\], and hormone replacement therapy use \[[@CR65]\], are possibly confounding factors taking part in the disease etiology. Moreover, differences in patient choosing criteria, ethnicity, sample size, and sources of control could contribute to inconsistency. Hence, it is necessary to conduct a meta-analysis providing quantitative approach for pooling the results of all studies with the same purpose and explaining the overall estimation as well as the diversity.

Our study has important strengths. All original studies used a case-control study design, which is a useful tool to identify gene and disease associations. However, individual genotype case-control studies could not be based on a large number of subjects or contain patients in different ethnicities, and thus has insufficient statistical power. Our meta-analysis based on case-control studies involving 40,985 subjects brings to light that there is no significant association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility for overall population, with ORs from 0.99 to 1.00 and narrow 95 % CIs for all of the five genetic models. Moreover, in our study, no association was found in different ethnicities or in population-based studies, which thereby strengthened this association. As shown in our meta-analysis, studies with hospital-based design or controls deviated from HWE had a weak, but statistical significant decreased association with breast cancer in dominant model. However, in these two kinds of studies, the controls may not represent the whole population and thereby, the results from them should be interpreted with caution. Overall, our meta-analysis based on 38 case-control studies provided reliable and comprehensive estimations. The association in the five genetic models sustained unchanged in the sensitivity analysis, which further confirmed the results of main analysis.

It is also important to mention the heterogeneity existed in this study. For all genetic models in the main analysis, *P* value for heterogeneity was less than 0.05, indicating significant heterogeneity among the included studies. Finding the potential sources of heterogeneity is an important part of meta-analysis, which can greatly influence the results of the research. To detect the possible source of heterogeneity in our meta-analysis, we performed the subgroup analysis stratified by ethnicity, source of control, and deviation from HWE. When stratified by ethnicity and source of control, the heterogeneity was significantly decreased in Asian and population-based subgroups. Therefore, the different ethnicity and source of control may contribute to the overall heterogeneity. However, heterogeneity still existed in Caucasian, mixed ethnicity, and hospital-based control subgroups, suggesting that ethnicity and source of control did not fully explain the heterogeneity among studies. Further studies may try to explore in interactions between different factors and to minimize the heterogeneity in subgroups.

Several previous meta-analyses have been published to analyze the association between *MTHFR* gene polymorphisms and breast cancer susceptibility, and the majority of them concerned on *677C\>T* polymorphism \[[@CR66]--[@CR69]\]. Two studies published in 2014 have detected the *1298A\>C* polymorphism \[[@CR17], [@CR70]\]. The main result of our study was consistent with the previous meta-analyses. Comparing with these two studies, our study has some important improvements. In 2014--2015, some new studies were published and they were included in our meta-analysis. Through strict methodological process, we provided a more comprehensive view of included studies. The abovementioned meta-analyses only stratified by ethnicity to test if there existed differences in variant ethnicities. In present study, we also conducted subgroup study stratified by source of control and deviation from HWE in control group, to analyze if there were differences between subgroups.

We should also pay attention to the several limitations in our study, which may affect the result. Firstly, we only included published studies meeting our inclusion criteria from two databases, similar studies in other databases and unpublished researches may have been missed, and this is also the main reason for the publication bias we found in four of the five genetic models. Secondly, the control groups in some of the included studies were deviated from HWE, which may fail to represent the whole population and have some effects on the overall estimation. Thirdly, although the results from subgroup and sensitivity analyses were quite similar to the main analysis, significant heterogeneity was detected in all five genetic models of *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility. Different characteristics in study population and study design may contribute to the heterogeneity. Considering that meta-analysis is a kind of retrospective research and may easily be affected by methodological deficiencies of the included studies, we developed a detailed protocol before conducting this analysis, to ensure the quality of our research.

Conclusions {#Sec15}
===========

From the combination results of currently included studies, our meta-analysis suggested that there is no significant association between *MTHFR* gene *1298A\>C* polymorphism and breast cancer susceptibility for overall population.
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